PHARMAC and treatment of bipolar depression - The limits of utilitarianism

New Zealand Medical Journal

Volumn 119, Issue 1231, 2006, Pages

  Ellis, Pete ^a   Mulder, Roger ^b   Porter, Richard ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LAMOTRIGINE; LITHIUM CARBONATE; MOOD STABILIZER; OLANZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; TRIAZINE DERIVATIVE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEATH; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; EPILEPSY; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; MENTAL HEALTH SERVICE; NEW ZEALAND; PRACTICE GUIDELINE; RELAPSE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SUICIDE; DRUG CONTROL; DRUG SCREENING; ECONOMICS; LEGAL ASPECT; PUBLIC HEALTH;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG EVALUATION; HUMANS; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; TRIAZINES;

EID: 33645470655     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry. 2004;38:280-305.
2. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(Suppl.):1-50.
3. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17:149-73.
4. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5-69.
5. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part I: Treatment of bipolar depression. The World J Biol Psychiatry. 2002;3:115-24.
6. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. The World J Biol Psychiatry. 2004;5:120-35.
7. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-86.
8. National Collaborating Centre for Mental Health. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Draft for second consultation, February 2006. The National Institute for Health and Clinical Excellence.
9. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79-88.
10. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841-50.
11. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607-14.
12. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-24.
13. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
14. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry. 2004;65:204-10.
15. Nierenberg A, Ostacher M, Calabrese J, et al. Treatment-resistant bipolar depression: A STEP-BD Equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210-16.
16. Chen YW, Dilsaverv SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biological Psychiatry. 1996;39:896-9.
17. Grunze H. Reevaluating therapies for bipolar depression. J Clin Psychiatry. 2005;66(Suppl 5):17-25.
18. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537-47.
19. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-33.
20. Dennehy EB, Suppes T, Rush AJ, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med. 2005;35:1695-706.
21. Post RM, Weiss SR. Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clin EEG Neurosci. 2004;35:14-24.
22. Hlastala SA, Frank E, Kowalski J, et al. Stressful life events, bipolar disorder, and the "kindling model". J Abnorm Psychol. 2000; 109:777-86.
23. Minister of Health. Te Tāhuhu - Improving Mental Health 2005-2015: The Second New Zealand Mental Health and Addiction Plan. Wellington: Ministry of Health; 2005. Available online. URL: http://www.moh.govt.nz/ moh.nsf/by+unid/F2907744575A9DA9CC25702C007E8411?Open Accessed March 2006.
24. New Zealand Suicide Prevention Strategy: A Life Worth Living. (Annette Beautrais, personal communication; 2006).